Farmaxon solution for injections 250 mg/ml. 2 ml. ampoules №5

Description

Farmaxon Composition
active substance: citicoline;

1 ml contains 250 mg of citicoline in the form of sodium salt;

excipients: diluted hydrochloric acid or sodium hydroxide, water for injection.

Farmaxon Dosage form.

Injection.

Basic physical and chemical properties: clear, colorless liquid.

Pharmacotherapeutic group. Psychostimulants, drugs used for attention deficit hyperactivity disorder (ADHD), nootropic drugs. Other psychostimulants and nootropics. ATX code N06B X06.

Farmaxon Pharmacological properties

Pharmacodynamics.

Citicoline stimulates the biosynthesis of structural phospholipids in the membrane of neurons, which improves the functions of membranes, including the functioning of ion-exchange pumps and neuroreceptors, the modulation of which is necessary for the normal conduction of nerve impulses. Due to the stabilizing effect on the membrane, citicoline exhibits decongestant properties, therefore, it reduces cerebral edema. Citicoline inhibits the activity of some phospholipases (A1, A2, C and D), prevents the residual formation of free radicals, prevents damage to membrane systems and ensures the preservation of protective antioxidant systems such as glutathione.

Citicoline reduces the volume of damaged tissue, preventing cell death, acting on the mechanisms of apoptosis, and improves cholinergic transmission. Citicoline also has a prophylactic neuroprotective effect in focal cerebral strokes.

Citicoline promotes rapid functional rehabilitation of patients with acute cerebrovascular accidents, reducing ischemic damage to brain tissue, which is confirmed by the results of X-ray studies.

In traumatic brain injury, citicoline shortens the recovery period and reduces the intensity of the post-traumatic syndrome.

Citicoline helps to increase the level of brain activity, reduces the level of amnesia, improves the condition in cognitive, sensory and motor disorders observed in cerebral ischemia.

Pharmacokinetics.

Citicoline is well absorbed by intramuscular and intravenous administration. After administration of the drug, there is a significant increase in the level of choline in the blood plasma.

Citicoline is metabolized in the intestine and liver to form choline and cytidine. After administration, citicoline is absorbed by the brain tissues, while cholines act on phospholipids, cytidine – on cytidine nucleoids and nucleic acids. Citicoline quickly reaches the brain tissue and is actively incorporated into cell membranes, cytoplasm and mitochondria, activating the activity of phospholipids.

Only a small amount of the administered dose is excreted in the urine and feces (less than 3%). Approximately 12% of the administered dose is excreted through the respiratory tract. Excretion of the drug in the urine and through the respiratory tract has two phases: the first phase is rapid excretion (with urine – within the first 36 hours, through the respiratory tract – within the first 15 hours), the second phase – slow excretion. The main part of the dose of the drug is involved in metabolic processes.

Clinical characteristics.

Indications
– Stroke, acute phase of cerebrovascular accidents and treatment of complications and consequences of cerebrovascular accidents.

– Traumatic brain injury and its neurological consequences.

– Cognitive and behavioral disorders due to chronic vascular and degenerative cerebral disorders.

Contraindications
– Hypersensitivity to the components of the drug.

– Increased tone of the parasympathetic nervous system.

Interaction with other medicinal products and other types of interactions.

Pharmaxone enhances the effect of levodopa. The drug should not be administered concurrently with medicinal products containing meclofenoxate.